INVA

Congress Trades

Actor	Trade Size	Last Transaction	Amount Range	Price	Current Price
George WhitesidesDemocrat $375k21.6k shares OtherMar 25, 2025 $250k-$500k $17.38 $22.13
George WhitesidesDemocrat $375k21.6k shares OtherMar 25, 2025 $250k-$500k $17.38 $22.13
George WhitesidesDemocrat $75k4.3k shares OtherMar 24, 2025 $50k-$100k $17.33 $22.13

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Raifeld PavelDirector, Officer: Chief Executive Officer --1.1k shares Grant / ExerciseMay 20, 2026 $25.1K1.1k shares $22.24 $22.13
Zhen MarianneChief Accounting Officer --1.1k shares Grant / ExerciseMay 20, 2026 $25.1K1.1k shares $22.24 $22.13
Basso StephenChief Financial Officer --559 shares Grant / ExerciseMay 20, 2026 $12.4K559 shares $22.24 $22.13
Basso StephenChief Financial Officer --1.1k shares Grant / ExerciseMay 15, 2026 Disclosure amount unavailable1.1k shares -- $22.13
Raifeld PavelDirector, Officer: Chief Executive Officer --1.1k shares Grant / ExerciseMay 15, 2026 Disclosure amount unavailable1.1k shares -- $22.13

News

seekingalpha.comInnoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 8

gurufocus.comInnoviva to Participate in Upcoming Investor Conferencesgurufocus.comJun 1

businesswire.comInnoviva to Participate in Upcoming Investor Conferencesbusinesswire.comJun 1

fool.comInnoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million Morefool.comMay 29

zacks.comInnoviva (INVA) Tops Q1 Earnings Estimateszacks.comMay 6

Trade INVA

About Innoviva, Inc.

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.

CEO: Pavel Raifeld
IPO Date: Oct 5, 2004

Market Data

Open: $22.53
High: $22.70
Low: $22.30
Volume: 722.4K
52W High: $25.15
52W Low: $16.52

Valuation

Valuation snapshot is not available yet.

Financials

Financial statement snapshot is not available yet.

Events

EarningsAug 5

EPS est. 0.436